Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000455 · ClinicalTrials.gov registry record · Phase 4
Naltrexone for Early Problem Drinkers
A Phase 4 study, sponsored by UConn Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
NCT00000455 is a Phase 4 study that has completed, run by UConn Health. The registered enrollment target is 160 participants.
The verdict
NCT00000455, a Phase 4 study, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
Study Summary
Early problem drinkers are prevalent in the United States. Recent controlled trials have shown that brief interventions in the primary care setting can reduce drinking and alcohol-related problems in patients who lack evidence of alcohol dependence. Although naltrexone (Revia) has been approved for the treatment of alcohol dependence, few pharmacotherapy studies have been undertaken with early problem drinkers. This study is an 8-week trial of naltrexone versus placebo, combined with coping skills treatment that either focuses on targeted use of medication or serves as background to daily use of the medication. A total of 160 early problem drinkers recruited through screening in primary care medical settings will be randomly assigned to one of four treatment groups. Followup evaluations will be conducted at the end of treatment and again 3, 6, and 12 months.
Interventions
- DRUG naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Est. Completion | 2002-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000455
The ClinicalTrials.gov registry entry for NCT00000455 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which naltrexone is the first listed.
NCT00000455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000455 about?
NCT00000455 is a clinical study titled "Naltrexone for Early Problem Drinkers". Early problem drinkers are prevalent in the United States. Recent controlled trials have shown that brief interventions in the primary care setting can reduce drinking and alcohol-related problems in patients who lack evidence of alcohol dependence. Although naltrexone (Revia) has been approved for...
What is the current status of trial NCT00000455?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 160 participants. Estimated completion is 2002-09.
What interventions are being tested in trial NCT00000455?
The interventions under investigation include: naltrexone (DRUG).
Who is sponsoring clinical trial NCT00000455?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.